Photo of Debra Tonetti

Debra Tonetti


Cancer Center Member, Cancer Center
Member of the Graduate College, Graduate College
Professor of Pharmacology, with tenure, College of Pharmacy - Pharmaceutical Sciences

Related Sites:

Teaching and Supervision

PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
Biopharmaceutical Sci II (BPS 502), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020

Selected Grants

Breast cancer virotherapy, National Institutes of Health (National Cancer Institute)., 4/1/2021 - 3/31/2023, Obligated Amount: $186883; Anticipated Amount: $411143

Targeting Serine Auxotrophy in Luminal Breast Cancer, National Institutes of Health (National Cancer Institute)., 3/1/2021 - 2/28/2026, Obligated Amount: $359689; Anticipated Amount: $1798445

A Novel Biomarker for TTC-352 Therapy Development., 5/15/2019 - 4/30/2020, Obligated Amount: $1000000; No Anticipated Amount Set

A novel biomarker for TTC 352 cancer therapy development, University of Illinois DPI Seed Funding Program., 5/1/2019 - 4/30/2020, No Obligated Amount Set; Anticipated Amount: $100000

A Novel BET Inhibitor for Breast Cancer Combinatiion Therapy, Chicago Biomedical Consortium., 1/1/2019 - 12/31/2019, Obligated Amount: $100000; Anticipated Amount: $100000

Incoming MTA - Baylor College of Medicine for Cell Lines, Baylor College of Medicine., 10/10/2018 - 10/9/2019, No Obligated Amount Set; No Anticipated Amount Set

Incoming MTA - Baylor College of Medicine, Baylor College of Medicine., 9/11/2018 - 9/10/2019, No Obligated Amount Set; No Anticipated Amount Set

Development of PET Probe for ER+ Breast Cancer, UICentre-CCTS Inception Grant., 7/1/2018 - 6/30/2019, No Obligated Amount Set; Anticipated Amount: $12500

Discovery of New Partners for Combination Therapy with G1T48, G1 Therapeutics Inc., 6/1/2017 - 5/31/2018, Obligated Amount: $350000; Anticipated Amount: $350000

Selected Publications

Abderrahman, B, Maximov, PY, Curpan, RF, Fanning, SW, Hanspal, JS, Fan, P, Foulds, CE, Chen, Y, Malovannaya, A, Jain, A, Xiong, R, Greene, GL, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2021). Rapid induction of the unfolded protein response and apoptosis by estrogen mimic ttc-352 for the treatment of endocrine-resistant breast cancer. Molecular Cancer Therapeutics, 20, (1), 11-25. doi:10.1158/1535-7163.MCT-20-0563.

Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer (vol 98, pg 364, 2020). MOLECULAR PHARMACOLOGY, 98, (4), 528-528.

Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Erratum: Pharmacology and molecular mechanisms of clinically relevant estrogen estetrol and estrogen mimic BMI-135 for the treatment of endocrine-resistant breast cancer (Molecular Pharmacology (2020) 98 (364-381) DOI: 10.1124/molpharm.120.000054). Molecular Pharmacology, 98, (4), 528. doi:10.1124/molpharm.120.000054err.

Dudek, AZ, Liu, LC, Fischer, JH, Wiley, EL, Sachdev, JC, Bleeker, J, Hurley, RW, Tonetti, DA, Thatcher, GRJ, Venuti, RP, O’Regan, RM. (2020). Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment, 183, (3), 617-627. doi:10.1007/s10549-020-05787-z.

Jordan, VC, MacGregor, JI, Tonetti, DA. (2020). Selective estrogen receptor modulators as a new postmenopausal prevention- maintenance therapy. Progress in the Management of the Menopause. (pp. 18-25). doi:10.1201/9781003076575-4.

Li, Y, Zhao, J, Gutgesell, LM, Shen, Z, Ratia, K, Dye, K, Dubrovskyi, O, Zhao, H, Huang, F, Tonetti, DA, Thatcher, GRJ, Xiong, R. (2020). Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Journal of Medicinal Chemistry, 63, (13), 7186-7210. doi:10.1021/acs.jmedchem.0c00456.

Jordan, VC, MacGregor, JI, Tonetti, DA. (2020). Selective estrogen receptor modulators as a new postmenopausal prevention- maintenance therapy. Progress in the Management of the Menopause. (pp. 18-25). doi:10.4324/9781003076575-4.

Andreano, KJ, Wardell, SE, Baker, JG, Desautels, TK, Baldi, R, Chao, CA, Heetderks, KA, Bae, Y, Xiong, R, Tonetti, DA, Gutgesell, LM, Zhao, J, Sorrentino, JA, Thompson, DA, Bisi, JE, Strum, JC, Thatcher, GRJ, Norris, JD. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment, 180, (3), 635-646. doi:10.1007/s10549-020-05575-9.

Lu, Y, Gutgesell, LM, Xiong, R, Zhao, J, Li, Y, Rosales, CI, Hollas, M, Shen, Z, Gordon-Blake, J, Dye, K, Wang, Y, Lee, S, Chen, H, He, D, Dubrovyskyii, O, Zhao, H, Huang, F, Lasek, AW, Tonetti, DA, Thatcher, GRJ. (2019). Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer. Journal of Medicinal Chemistry, 62, (24), 11301-11323. doi:10.1021/acs.jmedchem.9b01580.

Education

Degrees:
Doctor of Philosophy, Loyola University Chicago, United States, 1990
Master of Science, Loyola University Chicago, United States, 1985
Bachelor of Science, Northern Illinois University, United States, 1980

Postgraduate Training:
Enrico Fermi Postdoctoral Fellow, Argonne National Laboratory, United States, 1994